

Mariangela Figini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1917423/publications.pdf>

Version: 2024-02-01

67
papers

2,652
citations

249298

26
h-index

214428

50
g-index

69
all docs

69
docs citations

69
times ranked

4495
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 Vaccination in Health Care Workers in Italy: A Literature Review and a Report from a Comprehensive Cancer Center. <i>Vaccines</i> , 2022, 10, 734.	2.1	0
2	Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 5.	3.5	9
3	SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region. <i>Cancers</i> , 2021, 13, 1035.	1.7	2
4	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
5	Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. <i>Cancers</i> , 2021, 13, 4081.	1.7	5
6	Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review. <i>Biomedicines</i> , 2021, 9, 1870.	1.4	4
7	Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. <i>Cells</i> , 2020, 9, 2231.	1.8	8
8	Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 154, 246-258.	2.0	20
9	IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. <i>Cancers</i> , 2020, 12, 3376.	1.7	15
10	Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). <i>Scientific Reports</i> , 2020, 10, 8869.	1.6	11
11	Development of ¹⁷⁷ Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen. <i>Scientific Reports</i> , 2020, 10, 9313.	1.6	11
12	Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 326.	3.5	15
13	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2514.	2.2	7
14	Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 125.	3.5	72
15	An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2328-2341.	2.7	24
16	Selective targeting and degradation of doxorubicin-loaded folate-functionalized DNA nanocages. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1181-1190.	1.7	59
17	Anti-Folate Receptor Alpha-directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5098-5111.	3.2	65
18	Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. <i>Frontiers in Immunology</i> , 2018, 9, 493.	2.2	14

#	ARTICLE	IF	CITATIONS
19	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. <i>MAbs</i> , 2018, 10, 1084-1097.	2.6	17
20	Anti-Folate Receptor- α IgE but not IgG Recruits Macrophages to Attack Tumors via TNF α /MCP-1 Signaling. <i>Cancer Research</i> , 2017, 77, 1127-1141.	0.4	58
21	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. <i>Frontiers in Immunology</i> , 2017, 8, 1112.	2.2	17
22	Deregulated MicroRNA-21 Expression in Monocytes from HIV-Infected Patients Contributes to Elevated IP-10 Secretion in HIV Infection. <i>Frontiers in Immunology</i> , 2017, 8, 1122.	2.2	16
23	Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. <i>Oncotarget</i> , 2017, 8, 10919-10930.	0.8	17
24	Targeting folate receptor alpha for cancer treatment. <i>Oncotarget</i> , 2016, 7, 52553-52574.	0.8	308
25	In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. <i>Scientific Reports</i> , 2016, 6, 23314.	1.6	36
26	Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. <i>Journal of Hematology and Oncology</i> , 2016, 9, 56.	6.9	97
27	A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. <i>Oncotarget</i> , 2015, 6, 21533-21546.	0.8	76
28	Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 2570-2573.	1.5	16
29	Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. <i>Immunology Letters</i> , 2015, 168, 105-110.	1.1	11
30	Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo. <i>Nanoscale</i> , 2015, 7, 2336-2351.	2.8	27
31	Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. <i>Oncotarget</i> , 2015, 6, 28911-28928.	0.8	45
32	PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models. <i>PLoS ONE</i> , 2014, 9, e109427.	1.1	64
33	Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats. , 2014, , 83-90.		0
34	Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. <i>Future Oncology</i> , 2013, 9, 527-539.	1.1	35
35	A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. <i>European Journal of Cancer</i> , 2013, 49, 2223-2232.	1.3	47
36	CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. <i>Blood</i> , 2012, 119, 696-706.	0.6	296

#	ARTICLE	IF	CITATIONS
37	Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4. <i>PLoS ONE</i> , 2011, 6, e22081.	1.1	6
38	Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of Fc ϵ R1-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1400-1413.	1.4	38
39	Antitumor Effects of a Human Dimeric Antibody Fragment ¹³¹ I-AFRA-DFM5.3 in a Mouse Model for Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1938-1946.	2.8	14
40	<i>In Vivo</i> Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). <i>Cancer Research</i> , 2011, 71, 4617-4627.	0.4	256
41	Anti-FR Antibody Generation and Engineering: Development of New Therapeutic Tools. , 2011, , 151-179.		0
42	Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. <i>Journal of Cellular Physiology</i> , 2010, 225, 256-265.	2.0	28
43	Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 531-546.	2.0	23
44	¹⁷⁷ Lu- labeled MOv18 as compared to ¹³¹ I- or ⁹⁰ Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. <i>Nuclear Medicine and Biology</i> , 2009, 36, 759-770.	0.3	26
45	Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. <i>Journal of Translational Medicine</i> , 2009, 7, 101.	1.8	5
46	Dissecting the Structural Determinants of the Interaction between the Human Cytomegalovirus UL18 Protein and the CD85j Immune Receptor. <i>Journal of Immunology</i> , 2008, 180, 957-968.	0.4	10
47	Activation of the Osteopontin/Matrix Metalloproteinase-9 Pathway Correlates with Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2008, 14, 7470-7480.	3.2	99
48	Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction. <i>Journal of Immunotherapy</i> , 2007, 30, 684-693.	1.2	70
49	Complement Activated by Chimeric Anti-Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma. <i>Cancer Research</i> , 2006, 66, 3876-3883.	0.4	36
50	The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6170-6178.	3.2	87
51	775. Folate Receptor Targeted Virotherapy of Ovarian Cancer Using a Tropism Modified Measles Virus. <i>Molecular Therapy</i> , 2006, 13, S300.	3.7	0
52	Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. <i>Journal of Gene Medicine</i> , 2005, 7, 158-170.	1.4	26
53	⁹⁰ Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 1200-1213.	2.0	39
54	CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5202-5214.	3.2	52

#	ARTICLE	IF	CITATIONS
55	A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. <i>Oncogene</i> , 2004, 23, 7552-7560.	2.6	25
56	Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection. , 2003, 207, 145-160.		1
57	Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. <i>Gene Therapy</i> , 2003, 10, 1018-1025.	2.3	68
58	Isolation of Human Monoclonal Antibodies Using Guided Selection with Mouse Monoclonal Antibodies. , 2002, 178, 207-217.		2
59	Re: Blocking Oncogenic Ras Signaling for Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1031-1032.	3.0	11
60	Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2. <i>Cancer Immunology, Immunotherapy</i> , 2001, 49, 679-686.	2.0	7
61	Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to $\hat{I}\pm$ -folate receptor overexpression. <i>Oncogene</i> , 2000, 19, 4754-4763.	2.6	74
62	Single-step purification of immunotoxins containing a high ionic charge ribosome inactivating protein clavin by carboxymethyl high-performance membrane chromatography. <i>Journal of Chromatography A</i> , 1999, 830, 329-335.	1.8	6
63	Approaches to implement bispecific antibody treatment of ovarian carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 1997, 45, 187-189.	2.0	6
64	New Techniques for the Production of Therapeutic Recombinant Human Monoclonal Antibodies. <i>BioDrugs</i> , 1995, 4, 301-311.	0.7	1
65	In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation. <i>Journal of Molecular Biology</i> , 1994, 239, 68-78.	2.0	76
66	Glycolipids carrying Ley are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1. <i>International Journal of Cancer</i> , 1992, 51, 225-231.	2.3	18
67	Characterization of a mouse-human chimeric antibody to a cancer-associated antigen. <i>International Journal of Cancer</i> , 1992, 52, 588-593.	2.3	8